Gamida Cell Ltd., a maker of cell and immune therapy technologies, on Wednesday published the results of a key late-stage clinical trial of its flagship drug, which aims to increase the success of bone marrow transplants in blood cancer patients triggering a surge in its Nasdaq-traded shares.
Gamidas shares jumped almost 26% on the US exchange Wednesday. The shares have advanced 163% in the past 12 months, leading to a company valuation of $733 million. The firm held its initial public offering of shares on the Nasdaq in 2019 to help finance the final stage trial of the drug.
The phase three study tested the safety and efficacy of its omidubicel drug, previously called NiCord, in patients with blood-based cancers.
Get The Start-Up Israel's Daily Start-Up by email and never miss our top storiesFree Sign Up
The data showed that omidubicel resulted in faster blood count recovery, fewer bacterial and viral infections, and fewer days in the hospital.
Stem cells in bag in Gamida Cells Jerusalem lab, July 2017 (Shoshanna Solomon/TimesofIsrael)
All of these are meaningful results and represent potentially important advancements in care when considering the patient experience following transplant, said Mitchell Horwitz, principal investigator and professor of medicine at the Duke Cancer Institute, in a statement released by the Jerusalem-based firm.
The data was from the international, multi-center, randomized Phase 3 study of the drug, designed to evaluate the safety and efficacy of omidubicel in patients with high-risk hematologic malignancies undergoing a bone marrow transplant compared with a group of patients who received a standard umbilical cord blood transplant.
In May, the firm said that the study yielded positive results and met a major target showing that omidubicel led to a statistically significant reduction in the time needed to for patients to begin making healthy new cells after receiving stem cells, which is a key milestone in a patients recovery from a bone marrow transplant.
Omidubicel, which would be the first drug developed by Gamida to hit the market, is believed to increase the chances of a successful bone marrow transplantation process for patients who do not have a rapidly available, fully matched bone marrow donor.
Julian Adams, chief executive officer of Gamida Cell (Courtesy)
Despite the curative potential of bone marrow transplant, it is estimated that more than 40 percent of eligible patients in the United States do not receive a transplant for various reasons, including the lack of a matched donor.
Today some high-risk blood cancers cannot be cured unless the patient undergoes a bone marrow graft. For that purpose, a perfect match needs to be found, a process that in the US takes an average of three to four months, if the patient is lucky. Sometimes, no match is found.
Umbilical cord blood collected from newborn babies contains stem cells, which can be used to treat diseases. Today cord-blood banks around the world store the cord blood. Its great advantage is that because it is so young, there is no need for a full tissue matching and a partial match is enough. Most patients generally find at least one unit of cord blood that partially matches them.
The problem is that the quantity of cells in each unit is not huge, and it is the number of stem cells in the cord blood that is critical to the success of transplantation.
Gamida overcomes this limitation by expanding the number of stem cells within one unit of umbilical cord blood and enhancing their performance.
The firm said Wednesday that it expects to submit a Biologics License Application to the US Food and Drug Administration for omidubicel in the second half of this year.
We believe that omidubicel has the potential to transform the field of hematopoietic bone marrow transplant by expanding access to this potentially curative cell therapy treatment for thousands of patients who are in need of a transplant but lack access to a matched related donor, said Julian Adams, chief executive officer of Gamida Cell, which was founded in 1998.
Youre serious. We appreciate that!
Were really pleased that youve read X Times of Israel articles in the past month.
Thats why we come to work every day - to provide discerning readers like you with must-read coverage of Israel and the Jewish world.
So now we have a request. Unlike other news outlets, we havent put up a paywall. But as the journalism we do is costly, we invite readers for whom The Times of Israel has become important to help support our work by joining The Times of Israel Community.
For as little as $6 a month you can help support our quality journalism while enjoying The Times of Israel AD-FREE, as well as accessing exclusive content available only to Times of Israel Community members.
The rest is here:
- One year to test 200 Cordlife samples 'totally unjustified': Global cord blood banking experts - The Straits Times - April 15th, 2024
- Clinical trial: First cardiac bioimplants for treatment of myocardial infarction using umbilical cord stem cells - Medical Xpress - April 7th, 2024
- The umbilical cord: a rich and ethical stem cell source to advance ... - March 30th, 2024
- Story of discovery: getting a Notch up on cord blood cell ... - March 30th, 2024
- Cord Blood Transplants | Memorial Sloan Kettering Cancer Center - March 30th, 2024
- Therapeutic effect and study of human umbilical cord blood mononuclear cells in patients with ischaemic bowel ... - Nature.com - March 17th, 2024
- Global Cord Blood & Tissue Banking Industry Report 2024: The Vast Majority of the Global Cord Blood Market is Now ... - PR Newswire - March 15th, 2024
- Improving Transplant Outcomes and Cell Therapy Approaches - RegMedNet - March 9th, 2024
- The inhibition of ADAM17 in cord blood stem cell-derived CD16+ NK cells to enhance their cytotoxicity against acute ... - ScienceDirect.com - March 1st, 2024
- Beating Blood Cancer through Recycling - a Community crowdfunding project in Liverpool by Kate Williams - Crowdfunder UK - February 24th, 2024
- Cord Blood Registry (CBR ) by CooperSurgical and Fulgent Genetics Launch Innovative Genetic Testing - Investing.com Canada - February 9th, 2024
- Young cancer patient with 'no hope' of recovery saved by baby's umbilical cord - Study Finds - February 9th, 2024
- Global Cord Blood & Tissue Banking Industry Report 2024 - The Vast Majority of the Global Cord Blood Market is Now ... - ACROFAN - January 26th, 2024
- Finding the optimal combination of anticancer drug administration for the conditioning of cord blood transplantation - Medical Xpress - January 26th, 2024
- Cord Blood Banking Market Sales and Revenue Report 2023-2032 - WhaTech Technology and Markets News - January 26th, 2024
- Global Cord Blood & Tissue Banking Industry Report 2024 - The Vast Majority of the Global Cord Blood Market is Now ... - ACROFAN USA - January 24th, 2024
- Global Biobanking Market Size To Exceed USD 97.5 Billion By 2032 | CAGR of 5.8% - GlobeNewswire - January 24th, 2024
- The use of cryopreservation in life saving research - The Manufacturer - January 24th, 2024
- CD19-targeted CAR NK cell therapy achieves promising one-year results in patients with B-cell malignancies - Medical Xpress - January 18th, 2024
- Cord blood banking comes at a high cost to babies - STAT - STAT - January 18th, 2024
- Global Cord Blood and Tissue Banking Industry Gains Traction Amidst Surging M&A Activity and Technological Advances - PR Newswire - January 16th, 2024
- Donating Bone Marrow and Stem Cells: The Process and What To Expect - On Cancer - Memorial Sloan Kettering - January 11th, 2024
- Ask the doctors: Research being conducted on using stem cells to treat diabetes - The Spokesman Review - January 4th, 2024
- askST: Can cord blood units be transferred from one bank to another? - The Straits Times - December 27th, 2023
- Timeline: Cordlife's mishandling of cord blood units in Singapore - CNA - December 15th, 2023
- Next-Level Evolution: Enhancing the Human Body With Anthrobots ... - Securities.io - December 5th, 2023
- Fred Hutch at ASH: Gene therapies for sickle cell, how to improve ... - Fred Hutchinson Cancer Center - December 5th, 2023
- Enhancing the immunosuppressive properties of human umbilical ... - Phys.org - December 1st, 2023
- Global Status and Trends for Thromboangiitis Obliterans | JPR - Dove Medical Press - December 1st, 2023
- Early Stage Cell Therapy Trial Shows Promise in Treating Progressive Multiple Sclerosis - University of Colorado Anschutz Medical Campus - December 1st, 2023
- Global Medical Specialty Bag Market is Expected to Reach US$ 9.4 Billion by 2034, Rising at a Steady 4.7% CAGR | Future Market Insights, Inc. - Yahoo... - November 29th, 2023
- Repeated concussions can alter heart activity and impact the heart ... - Philippine Canadian Inquirer - November 29th, 2023
- Vita 34 increases revenue and earnings in Q3 2023 and further ... - PharmiWeb.com - November 27th, 2023
- Vita 34 increases revenue and earnings in Q3 2023 and further ... - Marketscreener.com - November 25th, 2023
- FY 2021 VA-Funded Projects - VA's Office of Research and Development - November 25th, 2023
- New study aims to expand access to stem cell transplant using ... - Healio - November 23rd, 2023
- Impact of GVHD Prophylaxis on CMV Reactivation and Disease ... - Cancer Network - November 23rd, 2023
- The Top 25 Women Leaders in Biotechnology of 2023 - The Healthcare Technology Report. - November 21st, 2023
- First Edition: November 20, 2023 - KFF Health News - November 21st, 2023
- An essential guide to the building blocks of life - Gates Notes - November 21st, 2023
- A Simple Way to Save Premature Babies - The New York Times - November 19th, 2023
- Perspectives of current understanding and therapeutics of Diamond ... - Nature.com - November 17th, 2023
- Brain Organoids: Should They Be Considered People? - BBVA OpenMind - November 17th, 2023
- Understanding the cause of childhood Alzheimer's - ASBMB Today - November 17th, 2023
- Peripheral nerve regeneration through nanofiber scaffolds | IJN - Dove Medical Press - November 15th, 2023
- Are STEM CELL EXOSOMES the secret to a 'snatched' jawline? Discover the products that influencers are claiming - Daily Mail - November 13th, 2023
- CAR-NK: The next generation in hematological malignancy treatment - News-Medical.Net - November 13th, 2023
- Regenerative Medicine | Top Regenerative Medicine Solution ... - Healthcare Tech Outlook - November 13th, 2023
- Stem cell therapy, emerging solution to slow down ageing - Punch Newspapers - November 13th, 2023
- Improving Cord Blood Transplantation Outcomes for Adults With ... - On Cancer - Memorial Sloan Kettering - November 11th, 2023
- 8 Ways To Save Lives With Canadian Blood Services & You Can ... - Narcity Canada - November 11th, 2023
- Internal investigation by Vita 34 AG reveals irregularities related to a ... - Marketscreener.com - November 11th, 2023
- 'We worried the worst would happen' - Yorkshire Children's Trust ... - The Yorkshire Post - November 11th, 2023
- Minor GPI(-) granulocyte populations in aplastic anemia and healthy ... - Nature.com - November 9th, 2023
- Repeated treatment with ProTrans is immunologically safe ... - Marketscreener.com - November 7th, 2023
- Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells - Benzinga - November 7th, 2023
- Health Canada issues warning on cord blood stored in Edmonton - CBC News - November 3rd, 2023
- Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting - Yahoo... - November 3rd, 2023
- Dynamic Stem Cell Therapy Uncovers Research in Advance ... - InvestorsObserver - November 3rd, 2023
- Go with the flow and achieve hearing restoration - Drug Discovery News - November 3rd, 2023
- Cell Therapy Market to Witness Exponential Growth by 2031 ... - Argyle Report - November 1st, 2023
- Cross-talk between Myeloid and B Cells Shapes the Distinct ... - Cancer Discovery - November 1st, 2023
- Comparison of effects of HucMSCs, exosomes, and conditioned ... - Nature.com - October 28th, 2023
- The structural and functional complexity of the integrative ... - Science - October 28th, 2023
- Global Primary Cells Market to Witness Growth at 11.41% CAGR to ... - GlobeNewswire - October 26th, 2023
- Hma-Qubec celebrates 25 years of giving life in anniversary ad - - The Message - October 26th, 2023
- Improvement of thermal-stability of chondroitinase ABCI immobilized ... - Nature.com - October 26th, 2023
- Sydney Couple Overcomes Sperm Antibody Issue to Welcome Baby - OPP.Today - October 24th, 2023
- New Research Reveals Surprising Issue with Sperm and Fertility - CityLife - October 24th, 2023
- Biobanking Market to Observe Prominent CAGR of 6.10% by 2029 ... - PharmiWeb.com - October 21st, 2023
- TV shows like BBC's Call The Midwife and C4's One Born Every Minute 'are inaccurately depicting childbirth' an - Daily Mail - October 19th, 2023
- Advances in medical and technological research and SCI - Clyde & Co - October 18th, 2023
- Prognostic Value of Hematogones in Patients With Hematopoietic ... - Cureus - October 18th, 2023
- Stem-Cell Therapy: Filling Gaps in Oro-Maxillofacial Region - Cureus - October 18th, 2023
- The neonatal southern white rhinoceros ovary contains oogonia in ... - Nature.com - October 18th, 2023
- OMG: Sperm injury led to rare baby struggle - news.com.au - October 18th, 2023
- Experts Explain how MS Impacts the Eyes and Eye Health - Health Central - October 18th, 2023
- Newly identified stem cells can lure breast cancer to the spine - Science News Magazine - October 15th, 2023
- Cases of HIV cure | aidsmap - aidsmap - October 15th, 2023
- HokUS-10 scoring system predicts the treatment outcome for ... - Nature.com - October 13th, 2023
Recent Comments